Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ACADEMIA
ACADEMIA
- Japan’s First Guidelines for Hematological Malignancy Treatment Compiled by Japanese Society of Hematology
October 24, 2013
- President of Kyoto Prefectural University of Medicine Reprimanded Over Diovan Scandal, Diovan Study Chief Investigator Returns Retirement Allowance
October 17, 2013
- Shiga University of Medical Science to Unveil Diovan Probe Results at Month-End
October 16, 2013
- University of Tokyo Professor Says Results of Diovan Investigations Need to Be Made Open Globally
October 1, 2013
- National University Hospital Council Urges Immediate Check-Up on Hospital’s Clinical Research Systems
September 25, 2013
- AJMC to Unify COI Management Guidelines, Release Draft in December
September 24, 2013
- Use Double-Blind Method to Regain Confidence in Japanese Clinical Trials: Dr Yui of Kyoto Univ. Hospital
September 10, 2013
- The Lancet Announces Retraction of JIKEI Paper on Diovan Trial, Says There’s “Sufficient Doubt”
September 9, 2013
- Tokushukai Group to Cancel Use of Diovan Products at Its 66 Hospitals
August 28, 2013
- Go-Between Faculty Member for Ex-Employee and Osaka City University Received 4 Million Yen in Grants from Novartis
August 26, 2013
- Osaka City University Slams Lead Investigators of Diovan Trials; They “Knew of His Novartis Affiliation”
August 26, 2013
- JSMO Announces Guidance on Prevention and Treatment of Tumor Lysis Syndrome; Rasburicase Recommended for High-risk Patients
August 22, 2013
- Health Ministry’s Diovan Committee Should Question Bosses of Ex-Novartis Employee Too, Says Key Member
August 19, 2013
- JASDI Conducting Survey on Inconsistencies in Package Inserts of Similar Drugs; Will Come Up with Improvement Proposal by Year-End
August 19, 2013
- JSGM Initiates Plan to Unify Brand Names of Generic Fixed-dose Combination Drugs to Prevent Medication Errors
August 19, 2013
- St. Marianna University School of Medicine Hospital Ends Use of Diovan for Patients
August 16, 2013
- British Journal The Lancet Begins Process of Retracting JIKEI Heart Study
August 16, 2013
- Japan Hypertension Society Sets Up Ethics Committee amid Diovan Fuss
August 8, 2013
- Japan Hypertension Society Deletes Citations of JIKEI Study from Treatment Guidelines
August 8, 2013
- NCC Sets Sights on World’s Top Development Hub with New Exploratory Clinical Research Center
August 7, 2013
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…